Update on tocilizumab in rheumatoid arthritis: a narrative . . . Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, swelling, and stiffness, affecting approximately 1% of the adult population Tocilizumab (TCZ), a monoclonal antibody targeting the IL-6 receptor, has emerged
Tocilizumab (Actemra) - American College of Rheumatology Tocilizumab (Actemra) Tocilizumab (Actemra) is a biologic medication approved to treat adults with moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis complicated by interstitial lung disease, and juvenile idiopathic arthritis among other diseases
ACTEMRA® (tocilizumab) Rheumatoid Arthritis (RA) Treatment . . . ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Tocilizumab (Actemra®) - Johns Hopkins Arthritis Center Tocilizumab (Actemra®) What is Tocilizumab (Actemra®)? Tocilizumab is in a class of drugs called biologics Tocilizumab is a treatment for adults with moderate to severe rheumatoid arthritis (RA), giant cell arteritis, and polyarticular and systemic juvenile idiopathic arthritis
Tocilizumab | Arthritis UK Tocilizumab is a biological therapy for rheumatoid arthritis and juvenile idiopathic arthritis (JIA) Learn how it’s used, risks and side-effects
Tocilizumab Monotherapy or Combined With Methotrexate for . . . Key Points Question What is the efficacy and safety profile of subcutaneous tocilizumab as monotherapy or in combination with methotrexate for patients with rheumatoid arthritis (RA)? Findings In this randomized clinical trial involving 340 patients, subcutaneous tocilizumab, both as monotherapy and combination therapy, was superior to methotrexate monotherapy in achieving an American College
Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic . . . Objective To compare the benefit and safety of tocilizumab to placebo in patients with rheumatoid arthritis (RA) Methods We searched multiple databases for published randomized or controlled clinical trials comparing benefit and safety of tocilizumab to placebo, disease-modifying antirheumatic drugs (DMARD), or other biologics For dichotomous outcomes, we calculated the relative risk, and
IL-6 inhibitor for the treatment of rheumatoid arthritis: A . . . Abstract Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid arthritis (RA) It was developed in 2008, and its effectiveness is supported by evidence from all over the world based on its first decade of use Although the overall efficacy and safety profiles of TCZ are similar to those of tumor necrosis factor (TNF) inhibitors, TCZ displays certain
The Role of Tocilizumab in Managing Rheumatic Diseases Tocilizumab is used in the treatment of various rheumatic diseases, including rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis